Apr 30, 2025
In 2025, the United States launched a bold new wave of tariffs, targeting imports critical to the pharmaceutical and healthcare industries. These policies, driven by a push to strengthen domestic manufacturing, impose a 10% tariff on all imported goods, alongside steeper levies of up to 245% on Chinese active pharm...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper